Hypertension Caused by Lenvatinib and Everolimus in the Treatment of Metastatic Renal Cell Carcinoma

Multikinase inhibitors (MKI) and mammalian target of rapamycin (mTOR) inhibitors prolong progression-free (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC) by reducing angiogenesis and tumor growth. In this regard, the MKI lenvatinib and the mTOR inhibitor ev...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Int J Mol Sci
Hlavní autoři: Bendtsen, Mathias Alrø Fichtner, Grimm, Daniela, Bauer, Johann, Wehland, Markus, Wise, Petra, Magnusson, Nils E., Infanger, Manfred, Krüger, Marcus
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2017
Témata:
Review
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5578126/
https://ncbi.nlm.nih.gov/pubmed/28796163
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms18081736
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky